Subscribe to news email updates. Type 1 Diabetes Treatment
Disappoints in Trial Vaccine-based approach didn't affect
insulin needs or other markers. By Serena Gordon WEDNESDAY, Feb.
1 (HealthDay News) -- The latest trial of a drug called GAD-alum
to treat type 1 diabetes failed to show any significant
improvement in the common markers of the blood sugar disease.
The researchers, however, said they felt there were possible
reasons for the failure of the current trial, and that specific
groups of people still might benefit from GAD-alum. "Even if
this study failed to reach its primary outcome, there were quite
impressive results in certain subgroups, which supports the
concept of using auto-antigens in the therapy of recent-onset
type 1 diabetes," said study author Dr. Johnny Ludvigsson, a
professor in the division of pediatrics, in the department of
clinical and experimental medicine at Linkoping University in
Sweden. Results of the study are published in the Feb. 2 issue
of the New England Journal of Medicine